Atom Investors’s Intellia Therapeutics NTLA Stock Holding History

Atom Investors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$525K	Buy	31,022 +8,369	+37%	+$117K	0.05%	549
2026 Q1	$290K	Sell	22,653 -69,887	-76%	-$890K	0.02%	553
2025 Q4	$832K	Buy	+92,540	New	+$1.27M	0.07%	323
2024 Q1	–	Sell	-20,282	Closed	-$618K	–	648
2023 Q4	$618K	Buy	20,282 +6,247	+45%	+$180K	0.11%	245
2023 Q3	$444K	Buy	+14,035	New	+$544K	0.1%	253
2023 Q1	–	Sell	-9,767	Closed	-$341K	–	297
2022 Q4	$341K	Sell	9,767 -5,155	-35%	-$245K	0.17%	121
2022 Q3	$835K	Buy	+14,922	New	+$926K	0.29%	110

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Atom Investors's NTLA Position: Q2 2026 in Review

Atom Investors increased its Intellia Therapeutics (NTLA) stake by 37% in Q2 2026, buying an estimated $117K and bringing the position to 31,022 shares worth $525K. The position accounts for 0.05% of the portfolio, ranked #549.

Atom Investors first reported a position in NTLA in Q3 2022 and has held it in 7 quarters since. The position peaked at $835K in Q3 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Atom Investors held 31,022 shares of Intellia Therapeutics worth $525K as of Q2 2026.
Atom Investors bought 8,369 Intellia Therapeutics shares in Q2 2026, an estimated $117K.
Intellia Therapeutics made up 0.05% of Atom Investors's portfolio in Q2 2026, its #549 holding.
Atom Investors first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 7 quarters since.
Atom Investors's Intellia Therapeutics position peaked at $835K in Q3 2022.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.